An iridoid glycoside from Cornus officinalis balances intestinal microbiome disorder and alleviates alcohol-induced liver injury

[Display omitted] •Protective effect of iridoid glycoside extracted from Cornus officinalis on liver.•Cornel iridoid glycoside regulate oxidative stress and inflammation in liver.•Cornel iridoid glycoside maintain intestinal health.•Potential mechanism of cornel iridoid glycoside anti-alcoholic live...

Full description

Saved in:
Bibliographic Details
Published inJournal of functional foods Vol. 82; p. 104488
Main Authors Han, Xiao, Liu, Jia, Bai, Yingfeng, Hang, Aiwu, Lu, Tulin, Mao, Chunqin
Format Journal Article
LanguageEnglish
Published Elsevier Ltd 01.07.2021
Elsevier
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:[Display omitted] •Protective effect of iridoid glycoside extracted from Cornus officinalis on liver.•Cornel iridoid glycoside regulate oxidative stress and inflammation in liver.•Cornel iridoid glycoside maintain intestinal health.•Potential mechanism of cornel iridoid glycoside anti-alcoholic liver injury. The intestinal microbiota plays an important role in the occurrence and development of alcoholic liver disease (ALD). The aim of this study was to investigate whether the cornel iridoid glycoside (CIG) of Cornus officinalis Sieb. et Zucc. could protect against ALD through the gut-liver axis. The results showed that, compared to an alcohol treated group, CIG could inhibit the activities of AST, ALT and MDA, promote the activities of SOD, CAT and GSH, and reduce oxidative damage to the liver. CIG could significantly alter intestinal microbial diversity, reduce the presence of serum LPS and levels of TNF-α, IL-1β and IL-6 in the liver. In addition, CIG supplementation reduced the imbalance of intestinal microbiota caused by alcohol and improved intestinal barrier function. Therefore, CIG may have a beneficial effect in alcoholic liver disease by maintaining the stability of the intestinal microbiota. We propose CIG as a potential therapeutic and prophylactic compound in clinical treatment of ALD.
ISSN:1756-4646
2214-9414
DOI:10.1016/j.jff.2021.104488